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Cell wallAntimicrobial peptides (AMPs) are natural antibiotics produced by virtually all living organisms. Typically, AMPs
are cationic and amphiphilic and ﬁrst contacts with target microbes involve interactions with negatively charged
components of the cell envelope such as lipopolysaccharide (LPS), andwall- or lipoteichoic acids (WTA, LTA). The
importance of charge-mediated interactions of AMPs with the cell envelope is reﬂected by effective microbial
resistance mechanisms which are based on reduction of the overall charge of these polymers. The anionic poly-
mers are linked in various ways to the stress-bearing polymer of the cell envelope, the peptidoglycan, which is
made of a highly conserved building block, a disaccharide-pentapeptide moiety that also contains charged
residues. This structural element, in spite of its conservation throughout the bacterial world, can undergo
genus- and species-speciﬁc modiﬁcations that also impact signiﬁcantly on the overall charge of the cell envelope
and on the binding afﬁnity of AMPs. The modiﬁcation reactions involved largely occur on the membrane-bound
peptidoglycan building block, the so-called lipid II, which is a most prominent target for AMPs. In this review, we
focus on modiﬁcations of lipid II and peptidoglycan and discuss their consequences for the interactions with
various classes of AMPs, such as defensins, lantibiotics and glyco-(lipo)-peptide antibiotics. This article is part
of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
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Peptidoglycan forms an essential stress-bearing and shape-
maintaining layer in the bacterial cell envelope. Its biosynthetic pathwayial Resistance to Antimicrobial
l Microbiology, Meckenheimer
41.is the target of important classes of antimicrobials such as beta-lactams
and glycopeptides, and the polymerized cell wall is targeted by antimi-
crobial enzymes such as lysozyme. Cell wall biosynthesis requires a
complex multiprotein biosynthesis machinery whose components
need to be tightly coordinated in space and time and functionally
interlinked with the cell division-machinery as well as with the cyto-
skeleton [1,2]. As the cell wall is essential for prokaryotic cell integrity,
reproduction, virulence expression, or other functions, targeting and
disrupting peptidoglycan synthesis leads to irreversible dysfunctions in
the target cell.
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heteropolymer composed of linear glycan chains of alternating ß-
(1–4)-linked units of N-acteylglucosamine and N-acteyl muramic acid
residues which are cross-linked by a peptide bond between peptide
subunits (Fig. 1). Lipid II represents the central cell wall building block
of peptidoglycan biosynthesis that is structurally conserved among
eubacteria. The basic structure of the precursor consists of the
bactoprenol carrier C55-P, which is linked to the disaccharide unit
N-acetyl-muramyl-pentapeptide-N-acetyl-glucosamine (MurNAc-
pp-GlcNAc) via a pyrophosphate bridge. The biosynthesis of PG is a
multistep process which requires numerous enzymatic reactions,
occurring in three compartments of a bacterial cell; the cytoplasm
(synthesis of nucleotide-bound precursors), the inner face of the mem-
brane (synthesis of the cell wall building block lipid II and lipid II mod-
iﬁcations) and the outer face of the membrane (polymerization of lipid
II into the growing PG network). In detail, biosynthesis starts in the
cytoplasm (Fig. 1), where the MurA-F ligases catalyze the formation of
the ultimate soluble cell wall precursor UDP-MurNAc-pentapeptide
[3–7]. In the following membrane associated step, UDP-N-acetyl-
muramic acid pentapeptide is linked to the membrane carrier
undecaprenol-phosphate (C55-P) by the translocase MraY, resulting in
the formation of lipid I (undecaprenylphosphate-MurNAcpentapeptide).
Proceeding cell wall biosynthesis, the membrane-associated transferase
MurG subsequently links UDP-GlcNAc to the N-acetylmuramic acid
moiety of lipid I, yielding lipid II (undecaprenylphosphate-GlcNAc-
MurNAcpentapeptide) [4,7,8]. The central cell wall building block lipid
II can be further modiﬁed strain dependently and in response to envi-
ronmental changes.
The fully modiﬁed lipid II is ﬁnally translocated across the
cytoplasmicmembrane engaging FtsWﬂippase activity [9] and incorpo-
rated into the growing peptidoglycan network through the activity of
the penicillin-binding proteins (PBPs) by transglycosylation andFig. 1. Schematic representation of cell wall biosynthesis; exemplary of the gram-positive path
cosamine (UDP-GlcNAc) to the ﬁnal soluble precursor UDP-MurNAc-pentapeptide (UDPMu
membrane-linked step, lipid I (undecaprenylphosphate-MurNAc-pentapeptide) is formed at th
peptide to the lipid carrier undecaprenylphosphate (C55-P). The translocase MurG sub
(undecaprenylphosphate-GlcNAc-MurNAcpentapeptide). In S. aureus, lipid II is further modiﬁe
in position two of the stempeptide is amidated to glutamine by the bi-enzyme complexMurT/G
units are incorporated into the growing peptidoglycan network through the activity of PBPs bytranspeptidation reactions [8,10,11], releasing C55-PP, which after
dephosphorylation enters a new synthesis cycle.
Despite the small size of themolecule, lipid II offers several different
binding sites for antibiotics which upon binding generally cause
sequestration of the precursors from PBPs and subsequent blocking of
transglycosylation and transpeptidation reactions (Fig. 2). In some
cases the interactions with lipid II may also trigger additional cellular
events which positively contribute to the potency of the antibiotics.
2. Lipid II binding AMPs
Cationic antimicrobial peptides (AMPs) are produced by all
living organisms including bacteria and come in many different
chemical structures including ribosomal peptides (e.g. linear helical or
disulphide-stabilized), ribosomal peptides with extensive posttransla-
tional modiﬁcations (so-called RIPPs) [12], such as lantibiotics as well
as peptides with unusual amino acids of non-ribosomal origin [13]
such as glyco- and lipopeptide antibiotics. The unifying structural and
biophysical theme of AMPs is the cationic and amphiphilic nature
which enables the interactionwith the negatively charged cell envelope
components and phospholipids. Based on these features, it was a long-
held view that AMPs kill microbes by forming more or less deﬁned
pores in the lipid bilayer of microbial membranes [14]. However, more
recently it became that the antibiotic activity even of unmodiﬁed ribo-
somal peptides can be much more speciﬁc and targeted (for review
[15]) and that particularly lantibiotics [16] and subgroups of disulﬁde-
stabilized defensins target the central cell wall building block lipid II
(Fig. 2).
Disulﬁde-stabilized defensins constitute a major class of eukaryotic
AMPs [17] and are produced by humans, animals, plants and fungi
where they play an important role in the innate immune system. In
2010 Schneider et al. [18] were able to demonstrate that the antibioticogen S. aureus. Synthesis starts in the cytoplasm with the conversion of UDP-N-acetyl-glu-
rNAc) as catalyzed by the sequential action of the MurA to MurF enzymes. In the ﬁrst
e inner face of the membrane by MraY, which transfers the soluble UDP-MurNAc-penta-
sequently inks UDP-GlcNAc to the muramoyl moiety of lipid I, producing lipid II
d by the addition of 5 glycine residues, catalyzed by FemXAB enzymes and the glutamate
atD. Finally, lipid II is translocated across themembrane. On the outside, the peptidoglycan
transglycosylation and transpeptidation reactions.
Fig. 2. Chemical structure of lipid II and prominent AMP binding sites. The binding site of vancomycin and related glycopeptides is marked in red. All other AMPs described so far to bind
lipid II interact with the pyrophosphate-sugar moiety marked in blue.
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binding lipid II, thereby inhibiting cell wall biosynthesis. With a series
of in vivo and in vitro data, an effect of plectasin on the integrity of the
cyplasmic membrane could be completely ruled out. In the meantime
in accordance to plectasin, a speciﬁc lipid II-targeting mode of action
has been described for several other defensins, belonging to various
subgroups. For example, binding of lipid II in vitro was demonstrated
for the fungal defensins oryzeasin (from Aspergillus oryzea) and eurocin
(from Eurotium amstelodami) [19], as well as for the antibacterial inver-
tebrate defensins lucifensin (from maggots of the blowﬂy Lucilia
sericata) and gallicin (from the mussel Mytilus galloprovinciali) [19].
These defensins all belong to a rather conserved family of AMPs [15],
however, evidence was presented in themeantime, that alsomammali-
an defensins, in particular human ß-defensin 3 (hBD3) [20] and humanFig. 3. Structures of different antimicrobial peptides (A) 3-dimensional structure of the fungal d
the pyrophosphate-binding pocket. In thisHADDOCK generatedmodel, the pyrophosphatemoi
bridge with the N terminus of plectasin and the side-chain of His18. (C) Chemical structures of
highlighted. (E) Structure of the lantibiotic nisin. Known lipid II binding motif is highlighted. Fα-defensin 1 (hNP1) [21], bind lipid II and block cell wall biosynthesis,
although the afﬁnity of these peptides for lipid II appears to be one
order of magnitude lower than that of plectasin-like defensins.
Among the most prominent examples of bacterial AMPs are the
heavily modiﬁed lantibiotics, a class of bacteriocins that were named
after their characteristic lanthionine or methyllanthionine residues.
Their structure can be either elongated, for example in nisin (Fig. 3) or
subtilin, or globular, as is the case for mersacidin or actagardine [22].
The activity of lantibiotics is based on different killing mechanisms
which may be combined in one molecule. Nisin which was the ﬁrst
lantibiotic discovered in the 1920s [23], is produced by some
Lactococcus lactis and widely used as a food preservative for more than
40 years. Like many lantibiotics nisin inhibits growth of Gram-positive
bacterial strains by interfering with peptidoglycan formation throughefensin plectasin (B) NMR-basedmodel of the plectasin/Lipid II-complex, detailed view of
ety forms hydrogen bonds to F2, G3, C4, and C27, and the D-glutamate of Lipid II forms a salt
the glycopeptides vancomycin and oritavancin (D). Additional residues of oritavancin are
igures taken from [18] (A, B) [98] (C, D), [16] (E).
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precursor in a stable complex and thereby blocking the entire peptido-
glycan synthesis cycle. The interaction between the lantibiotic and its
target primarily involves the formation of ﬁve hydrogen bonds between
the pyrophosphate moiety of lipid II and the amide backbone of the N-
terminal ring pair [27]. Additionally, nisin combines this activity with a
unique target-mediated pore formation, using lipid II as a docking
molecule, causing dissipation of the membrane potential, and rapid
efﬂux of small metabolites [24,25]. Sequestration of lipid II by nisin
also results in delocalization of the precursor and aberrant septum
formation [28–30]. The binding motif of nisin (Fig. 3) is conserved
among a number of lantibiotics targeting lipid II, for example, subtilin,
epidermin, gallidermin, plantaricin C, and mutacin 1140 [31]. In
contrast, type B lantibiotics like mersacidin and related peptides have
a globular structure, and solely act on binding to lipid II and blocking
its incorporation into peptidoglycan without causing additional effects
on the bacterial membrane [32].
In addition to ribosomally synthesized antimicrobial peptides,
microbes further produce peptide antibiotics of broad structural diversi-
ty using large multifunctional enzymes, the so-called nonribosomal-
peptide synthetases [33]. Some prominent examples of nonribosomally
synthesized peptides include the cationic peptides polymyxin B and
Gramicidin S that are used in the topical treatment of infections,
as well as the small circular metallo-peptide bacitracin [34,35],
or lipodepsipeptides such as ramoplanin or enduracidin [36] the
lipopeptide daptomycin, which has become an important reserve anti-
biotic against multiply resistant Gram-positive bacteria, as well as the
glycopeptides.
Glyocopeptides are one of the oldest classes of antibiotics, with
vancomycin (Fig. 3) as the prototype glycopeptide antibiotic, isolated
from fermentation broths of the soil bacterium Streptomyces orientalis
(now Amycolatopsis orientalis) in the early 1950s [37]. Vancomycin
and other glycopeptide antibiotics interrupt cell-wall biosynthesis in
Gram-positive bacteria by binding to the D-Ala–D-Ala dipeptide termi-
nus of the peptidoglycan cell-wall precursor lipid II [38,39], thereby
blocking the entire peptidoglycan synthesis cycle by shielding the
precursor from the penicillin binding proteins (PBPs) that catalyze
transglycosylation (polymerization) and transpeptidation (cross-
linking) [39,40]. The stoichiometric interaction between vancomycin
and the C-terminal D-Ala–D-Ala dipeptide of the PG precursor lipid II is
characterized by ﬁve hydrogen bonds and additional hydrophobic
interactions.
Manymore examples and classes of antimicrobial peptides exist and
have been extensively reviewed elsewhere (see, for example, [17,
41–43]).3. Lipid II modiﬁcations and their role in bacterial resistance to
antimicrobial peptides
Bacteria have developed a broad range of AMP resistance mecha-
nisms which include drug-speciﬁc responses such as proteolytic
degradation [44], as well as less speciﬁc strategies such as bioﬁlm for-
mation [45] and AMP detoxiﬁcation by transporters. The best studied
AMP resistancemechanisms in bothGram-positive and -negative bacte-
ria involve modiﬁcation of anionic cell surface constituents; the net
effect of these substitutions is to repel positively-charged AMPs before
they can reach the cytoplasmic membrane and disrupt its integrity.
The best understood mechanisms in this context are D-alanylation of
polyanionic teichoic acids (TAs), catalyzed by the DltABCD system
[46–49], and lysinylation of membrane phospholipids by MprF
[50–52]. In Gram-negative bacteria, masking of the negative charges
of the cell envelope mainly involves the addition of amine-containing
compounds such as ethanolamine and 4-amino-4-deoxy-T-arabinose
(Ara4N) to lipid A [53], the lipid component of the Gram-negative lipo-
polysaccharide (LPS).The systems modulating the cell surface charge mentioned above
are regulated, i.e. cellular damage caused by AMPs or the AMPmolecule
itself are sensed by respective two-component regulatory systems such
as GraRS in Gram-positive cocci and PhoP/Q in Gram-negative rods
which then upregulate the activity of the corresponding modulation
systems such as DltABCD to reduce AMP binding [54,55]. In contrast,
the modiﬁcations of the peptidoglycan structure discussed below tend
to be constitutive.Most of themodifying reactions occur on the peptido-
glycan building block lipid II which subsequently is a substrate for
transglycosylation and transpeptidation reactions. It can be speculated
that, in the course of evolution, the enzymes catalyzing the polymeriza-
tion reactions have been optimized to handle the modiﬁed lipid II
substrates only. It has been shown, for example, that the staphyloccocal
peptidogylcan synthesis machinery cannot handle lipid II variants with
modiﬁcations that are present in other species (e.g. [56]). Structural
details of themost frequentmodiﬁcations described below are depicted
in Fig. 4A.3.1. Variation of the lipid II peptide moiety
The peptidemoiety of the central cell wall precursor lipid II is bound
through its N-terminus to the carboxyl group of muramic acid and
contains alternating L- and D- amino acids. The occurrence of amino
acids with the D-conﬁguration is a typical feature of the bacterial pepti-
doglycan. In general, variationswithin the stempeptide can either occur
during its biosynthesis in the cytoplasm through enzymatic activity of
the speciﬁcMur-ligases, or at themembrane-bound stage after comple-
tion of the lipid II molecule. Usually L-alanine is bound to muramic acid,
but in some cases it can be replaced by glycine or L-serine. Differences at
this position observed for some Mycobacteria species could be traced
back to different growth conditions [57]. The second amino acid,
added by the MurD transferase, is glutamic acid in all known species
so far. This amino acid can be amidated to glutamine which will be
discussed below. The highest number of variations is found for the
amino acid in position 3 of the stem peptide which is added by a
species-speciﬁc MurE-ligase. This amino acid generally belongs to the
groupof diamino-acids, eithermeso-diaminopimelic acid (DAP),mostly
found in Gram negative bacteria, Mycobacteria or Bacilli, or L-lysine in
most Gram-positive bacteria. In some species other diamino-acids like
L-ornithine, D-lysine or L-2,4-diaminobutyricacid are found [58]. The
amino group of the L-diamino acid, not bound in the peptide subunit,
can form a peptide linkage to the C-terminal D-alanine of an adjacent
peptide subunit or can be substituted through an interpeptide-bridge.
The diversity of the bacterial interpeptide-bridges and its potential as
an interactions site with antibiotics will be separately discussed later
on. Following the synthesis of the stem peptide, the amino acids at
position 4 and 5 are usually added as a dipeptide, mostly D-Ala–D-Ala
which is pre-formed by enzymatic activity of the Ddl-ligase, following
incorporation into the stem peptide by the MurF-ligase. MurF-ligases
usually are characterized by broad substrate acceptance and therefore
also catalyze the addition of alternative dipeptides into the stempeptide
subunit [59].
A prominent example are vancomycin resistant strains, in which
D-lactate or D-serine replace the last D-alanine in position 5 of the
stem peptide. These strains have acquired a transposon (Tn1546),
mediating the production of the alternative dipeptide [60,61]
which is then added by the chromosomal encoded MurF-ligase. The
genetic information originates most probably from glycopeptide-
producing streptomycetes, which use the D-Ala–D-lactate version of
lipid II for self-protection. Vancomycin and other glycopeptide anti-
biotics usually interrupt cell-wall biosynthesis in Gram-positive
bacteria by binding to the D-Ala–D-Ala dipeptide terminus of
the peptidoglycan cell-wall precursor lipid II [38,39], thereby
blocking the entire peptidoglycan synthesis cycle by shielding the
precursor from the penicillin binding proteins (PBPs) that catalyze
Fig. 4. (A) Chemical structure of the cell wall precursor lipid II and its main modiﬁcations R = H or COOH for Lys and A2pm, respectively. Figure modiﬁed after [7]. (B) Structure of the
unmodiﬁed GlcNAc–MurNAc disaccharide (left side) and of selectedmodiﬁcations in the glycan part of peptidoglycan. The sites of attachment of surface polymers (teichoic acid, capsular
polysaccharide, arabinogalactan) via phosphodiester linkage are also indicated. Pep, peptide linked to MurNAc; LU, linkage unit; SP, surface polymer, modiﬁed after [109].
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linking) [39,40]. The stoichiometric interaction between vancomy-
cin and the C-terminal D-Ala–D-Ala dipeptide of the PG precursor
lipid II is characterized by ﬁve hydrogen bonds and additional
hydrophobic interactions. The mechanism of resistance results
from the replacement of the D-Ala–D-Ala peptidoglycan stem termi-
nus by D-Ala–D-Lactate or D-Ala–D-Serine, resulting in the loss of
one of the ﬁve hydrogen bonds between the aglycon of the antibiotic
and the terminal dipeptide structure of lipid II. This biosynthetic
alteration of the molecular target leads to a 1000-fold decrease of
vancomycins' antibiotic activity [62,63]. The evolution of bacterial
resistance to vancomycin has stimulated intensive research
activities on this class of antimicrobial peptides which led to the
development of interesting glycopeptide variants such as telavancin,
dalbavancin, and oritavancin [64–66] containing additional hydro-
phobic moieties to increase the antibiotics' amphiphilicity. The
lipoglycopeptide telavancin is characterized by an additional satu-
rated hydrocarbon chain which is thought to interact or disrupt the
cytoplasmic membrane barrier [67] and was recently approved by
the FDA for treatment of bacterial skin infections [68]. Similarly,
the semi-synthetic dalbavancin has a branched hydrocarbon
chain and is currently under development by Durata Therapeutics
Inc.
Oritavancin is a derivative of the natural product chloroeremomycin
and contains, in contrast to vancomycin, a halogenated biphenyl
group and an epi-vancosamine sugar moiety (Fig. 3). These additional
side chains confer oritavancin clinically signiﬁcant antibacterial
activity against vancomycin resistant- enterococci and S. aureus (VRE,
VRSA), methicillin resistant S. aureus (MRSA), and daptomycin-
nonsusceptible S. aureus [69–71]. Due to its unusual pharmacokinetics
[72,73] and its rapid bactericidal mode of action [74–76], oritavancin
has been approved in 2014 for the treatment of complicated skin andskin structure infections caused by Gram-positive pathogens. [77].
The enhanced antimicrobial activity of oritavancin, even against
vancomycin-resistant strains, where the stem peptide-termini are
modiﬁed to D-Ala–D-Lac, is due to multiple interactions with its molec-
ular target lipid II caused by the additional residues of the glycopeptides
antibiotic [78–80].
Solid-state nuclear magnetic resonance (NMR) and computational
modeling predicted secondary interactions of the 4′-chlorobip-
henylmethyl side chain with the S. aureus pentaglycine crossbridge
and the D-aspartate/D-asparagine (D-Asx) crossbridge in Enterococcus
faecium [56,81–84]. Very recently also biochemical evidence for the
interaction of oritavancin with the bacterial cross bridge as well as
D-iso-glutamine in position 2 of the lipid II stem peptide has been
given [56].3.2. Variation of the interpeptide-bridge
The nature of the interpeptide-bridge and the way of cross-linking
between neighboring stem peptides is highly variable among different
bacterial species and can be separated mainly into two groups [58].
The cross-linkage of group A extends from the ε-amino group of the
diamino acid in position 3 of one peptide subunit (acyl-acceptor) to
the carboxyl group of D-Ala in position 4 (acyl-donor) of another
adjacent peptide subunit. This 3–4 cross linkage is most common and
either occurs directly in most Gram-negative bacteria or via an
interpeptide-bridge mainly in Gram-positives. The second major
group of peptidoglycan cross-linkage extends from the α-carboxyl
group of D-Glu of one peptide subunit to the carboxylgroup of D-Ala of
an adjacent peptide subunit (2–4 cross-linkage), but is much less
frequent and found only among some plant pathogenic Corynebacteria
[58,85]. Since this cross-linkage occurs between two carboxyl groups,
3067D. Münch, H.-G. Sahl / Biochimica et Biophysica Acta 1848 (2015) 3062–3071a diamino acid has to be present in the interpeptide bridge. Generally,
the size of the interpeptide bridges ranges from two to seven amino
acid residues with great variety of used amino acids (e.g. Gly, L-Ala, L-
oder D-Ser, D-Asx, L- oder D-Glu). The vast diversity among the
interpeptide-bridge composition is in striking contrast to the knowl-
edge about the enzymes catalyzing these modiﬁcations (branching
enzymes). Even today, only a few enzymes are described and character-
ized in detail. According to Vollmer et al. [85] these enzymes can also be
classiﬁed into twomain groups, based on their catalytic activity. One en-
tails the addition of L-amino acids or glycine from aminoacyl-tRNAs via
enzymes of the family of Fem-transferases [86–89] while the other one,
which is ATP dependent andpresumably speciﬁc for D-amino acids, pro-
ceeds without aminoacyl-tRNAs [59,90,91]. The substrate of the
branching enzymes differs within different bacterial species. In Strepto-
coccus pneumoniae and S. aureus, lipid II was identiﬁed as the main
in vivo substrate for the assembly of the peptide bridge [86,88]. In
S. aureus the FemXAB peptidyltransferases are responsible for the
non-ribosomal, stepwise addition of ﬁve glycine molecules through a
tRNA mediated mechanism [86]. Biochemical work from Schneider
et al. [86] revealed that FemX initiates interpeptide-bridge formation
in S. aureus through speciﬁc addition of the ﬁrst glycine to the ε-
aminogroup of L-lysine within the peptide subunit of the lipid II mole-
cule. Further FemA catalyzes the addition of the second and third gly-
cine, following FemB with Gly4 and Gly5. Speciﬁc glycyl-tRNAs, which
get loaded in an ATP-dependent step by a glycyl-tRNA synthetase,
serve as glycine-donors in this reaction [92]. Furthermore, members of
the family of the Fem-transferases are also responsible for the addition
of 2 L-alanine-residues in E. faecalis (BppA1, BppA2; [87]), L-alanine in
Weissella viridescens (FemX; [89]) and L-serine-L-alanine or L-alanine-
L-alanine in S. pneumoniae (MurM, MurN; [88]). The assembly of the
peptide bridges seems to proceed in many cases on the lipid intermedi-
ates, however in Weissella viridescens, the in vivo addition of L-alanine
onto UDP-MurNAc-pentapeptide was substantiated by the presence of
a high UDP-MurNAc-hexapeptide pool and the absence of UDP-
MurNAc-pentapeptide [93].
As discussed earlier the interpeptide bridge provides an additional
binding site for the glycopeptide oritavancin, which thus has potent
activity towards vancomycin-resistant strains harboring a terminal D-
Ala to D-Lac in the lipid II stem peptide.
Until now the vanA-mediated mechanism of resistance is not evolv-
ing rapidly in MRSA [94]. Muropeptide analyses of vanA-type VRSA
revealed that these strains are characterized by complete lack or at
least severely shortened pentaglycine crossbridges [95]. It has been
shown that the simultaneous expression of chromosomally located
mecA and plasmid-borne vanA resistance determinants are mutually
antagonistic and it was concluded that this phenomenon is based on
the inefﬁcient recognition of depsipeptide precursors by the alternative
penicillin binding protein PBP2a [95,96]. Biochemical analysis of the
FemX- and FemXA-catalyzed reactions demonstrated that D-Lac
containing cell wall precursors are poor substrates for the staphylococ-
cal Fem-peptidyltransferases, presumably due to inference with sub-
strate recognition. Since pentaglycine bridge formation is severely
hampered in VRSA, a reduction in the activity of the Fem-transferases
results in abnormal cell morphology in the presence of oxacillin,
because PBP2a′ is unable to crosslinkmonoglycyl containing precursors
[81,97]. FemX of enterococci, in contrast, appears to efﬁciently recog-
nize depsipeptide precursors [87], which might partially explain
enhanced prevalence of VRE compared to VRSA.
Thus, in VRSA the interaction of oritavancin with the crossbridge
appears less relevant. Rather, as revealed by recent comparative analysis
of binding parameters [98], enhanced binding afﬁnity to lipid II-D-
Lac relies on additional interactions of oritavancin with D-iso-Gln in
position 2 of the stem peptide which facilitates stronger intramolec-
ular interactions with the PG precursor and thereby compensates
for the loss of a crucial hydrogen bond in vancomycin-resistant
strains.3.3. Amidation of glutamate in position 2 of the lipid II stem peptide
The peptidoglycan of staphylococci and other Gram-positive bacte-
ria, almost completely lacks free carboxyl groups since the α-carboxyl
group of D-glutamic acid at position 2 of the stem peptide is amidated,
resulting in the formation of D-iso-glutamine [58]. The physiological
role of this chemical modiﬁcation has remained a matter of speculation
for a long time and the genetic determinants and enzymes responsible
for the conversion of iso-glutamic acid to iso-glutamine residues have
been elusive. Siewert and Strominger already gave ﬁrst hints in 1968,
using a cell-free system with crude membrane preparations, that the
lipid bound precursors could serve as acceptors of ammonia in an
ATP-dependent reaction [99]. Several years later, a femC (factor essen-
tial for methicillin resistance) mutant was described exhibiting 48%
decreased muropeptide amidation [100], accompanied by a reduction
in methicillin resistance. The femC phenotype resulted from the disrup-
tion of the glutamine synthetase repressor glnR causing a polar effect on
glutamine synthetase (GlnA) expression, which in turn led to a drastic
reduction of the intracellular glutamine pool [100]. As external addition
of glutamine to themedium restored the femC defect [101], it suggested
that glutaminemay be the nitrogen donor for this reaction. On the func-
tional level, it has been hypothesized already early by Nakel et al. that
crosslinking of two adjacent stem peptides requires at least one of the
stem peptides involved to be amidated [102]. This is in accordance
with the observed reduction of peptidoglycan crosslinking in the femC
mutant, suggesting that non-amidated cell wall precursors are imper-
fect substrates for one ormore transpeptidases [81,82]. Characteristical-
ly, the PG of S. aureus is extensively crosslinked, with up to 95% of the
stem peptides interconnected [83]. On this account the coordinated
crosslinking plays a decisive role for S. aureus survival.
In 2012 the so far elusive enzymes that catalyze the amidation of the
peptidoglycan precursors were described and biochemical evidence for
acceptor and nitrogen donor substrates was given [86,103]. It could be
demonstrated that two enzymes, MurT and GatD, are necessary to
catalyze the amidation and that both enzymes form a stable heterodi-
meric complex [86]. MurT and GatD antisense depletion strains were
identiﬁed to display dramatically restored β-lactam susceptibility phe-
notypes amongMRSA isolates, emphasizing their commonparticipation
in PG biosynthesis and cell wall biogenesis. Zapun et al. [84] recently
reported the in vitro assembly of peptidoglycan using recombinant
penicillin-binding proteins from Pneumococcus and ﬁnally demonstrat-
ed that transpeptidase activity is favored by the amidation of the stem
peptides.
These new insights into the mechanism of lipid II amidation also
opened the opportunity for binding studies of the puriﬁed amidated
precursor and lipid II targeting AMPs. As already mentioned, compre-
hensive comparison of binding parameters of the glycopeptide
oritavancin (Fig. 3) to variants of the natural occurring cell wall building
block and its depsipeptide counterparts, ending in D-Ala–D-Lac, revealed
that amidation of the lipid II stem peptide accounts for increased bind-
ing afﬁnity of oritavancin in VRSA, rather than interaction with the
pentaglycine crossbridge, which is almost absent in these strains [95].
In contrast, such an increase in binding afﬁnity was not observed for
vancomycin. Rather, lipid II amidation appeared to strongly decrease
vancomycin binding afﬁnity, both in the in vitro system and as revealed
by determination of binding parameters. Earlier studies suggested a
correlation between vancomycin resistance and the reduced degree of
peptidoglycan amidation in S. aureus strain Mu50 [104]. Moreover, it
was shown that the antimicrobial activity of vancomycin is antagonized
more efﬁciently by short synthetic peptides (D-Glu/Gln-L-Lys-D-Ala–D-
Ala) containing D-iso-Glu instead of D-iso-Gln [82,104]. It has been
concluded that the increase in glutamine-non-amidated muropeptide
components in the peptidoglycan of Mu50may efﬁciently trap a higher
amount of vancomycin in the thickened cell wall. Contrary to
observations with vancomycin, enhanced binding afﬁnity to amidated
lipid II was also observed with chloroeremomycin, suggesting that the
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eremomycin, but absent in vancomycin, is involved in the interaction
with the amidated precursor.
The role of glutamate amidation has additionally been described in
the context of pathogenesis. Peptidoglycan is sensed by the human
innate immune system via NOD1 and NOD2 [105]; NOD1 recognizes
as minimal structure the D-Glu-meso-DAP dipeptide, typical of Gram-
negative bacteria, and is impaired by D-iso-glutamine presence suggest-
ing the involvement of this modiﬁcation in immune evasion. However,
the same was not observed for NOD2, whose binding activity to
muropeptides is not affected by the amidation of glutamic acid [106].
Since amidation of D-Glu also results in a less negatively charged PG,
a reduction of susceptibility towards innate defense mechanisms, by
means of cationic antimicrobial peptides could be observed. In line
with this, the fungal defensin plectasin showed increased efﬁcacy
against MurT/GatD depleted cells. Plectasin forms an equimolar (1:1)
complex with lipid II with its N-terminal amino group contributing to
binding through interaction with the carboxyl group of the D-Glu
residue (Fig. 3) [18]. Further, the availability of a conditional mutant of
MurT/GatD gave evidence for the importance of glutamine residues
for optimal growth rate, drug resistance and sensitivity of the staphylo-
coccal peptidoglycan to the host defense factor lysozyme [103].
Lysozyme acts on bacteria by hydrolyzing the β-1,4-glycosidic bonds
between the two sugar molecules of the glycan strands of peptidogly-
can. Besides this muramidase activity, lysozyme has also cationic anti-
microbial peptide activity due to its highly positive net charge [107].
Despite lipid II amidation, several other cell wall modiﬁcations have
been implicated in the lysozyme resistance mechanism of S. aureus
and other pathogens, namely a diversity ofmodiﬁcations of thepeptido-
glycan sugar backbone.
3.4. Variations in the glycan strand
As alreadymentioned above, one of themost abundant host antimi-
crobials onmucosal surfaces is themuramidase lysozyme,whichhydro-
lyses the glycan strands of peptidoglycan between C1 of MurNAc and C4
of GlcNAc. Lysozyme is secreted in large amounts by cells of the immune
system at sites of bacterial infection [108] and is also ubiquitous in
phages and fungi. Pathogens that colonize these sites have evolved
lysozyme resistance by modifying their peptidoglycan in order to pre-
vent lysis during early interactions with the host, and help bacteria to
establish infection by preventing release of bacterial products that can
initiate the host immune response.
Apart from its muramidase activity lysozyme also has AMP proper-
ties, due to its highly positive charge. Therefore reducing the overall
negative charge of the bacterial cell wall by introducing positive charge
residues, for example via amidation of the glutamate residue of the lipid
II stem peptide, contributes to lysozyme resistance.
Furthermoremodifying the sugar backbone of the peptidoglycan is a
common mechanism to avoid degradation by antimicrobial peptides
like lysozyme via its muramidase activity. The unmodiﬁed, polymerized
glycan strands consist of alternating β-1,4-linked GlcNAc and MurNAc
residue, however there are no bacterial species known to have such
unmodiﬁed glycan strands in mature peptidoglycan. Usually the glycan
strands become modiﬁed shortly after their synthesis, like 1,6-anhydro
ring formation at the terminal MurNAc-residue in the glycan strands of
most Gram-negative species, or the attachment of other cell-wall poly-
mers (e.g. teichoic acids, capsular polysaccharides) via phosphodiester
bonds, common to Gram-positive species. In addition,many pathogenic
species contain secondary glycan strand modiﬁcations also affecting
their interplay with factors of the immune system. The variety of the
so far known glycan strand modiﬁcations is summarized in Fig. 4B, for
a detailed description see reference [109,110].
Meanwhile, several enzymes responsible for these modiﬁcations
have been identiﬁed and characterized. The O-acetyltransferase A
(oatA) which is supposed to acetylate MurNAc at the C6 position wasidentiﬁed as the major determinant for lysozyme resistance in
S. aureus [111,112]. OatA was found to be encoded only in lysozyme-
resistant and pathogenic staphylococcal strains, and transformation of
a lysozyme-sensitive, nonpathogenic staphylococcal strain with the
S. aureus oatA gene was sufﬁcient to confer lysozyme resistance [111]
and was additionally found to provide protection against macrophage
killing and to restrict host cytokine responses [113]. OatA homologs
were found in the genome of S. pneumoniae [114], E. faecalis [115] and
L. lactis [116]. An unrelated peptidoglycan O-acetyltransferase protein
was identiﬁed in the Gram-negative pathogens Neisseria meningitidis
and Neisseria gonorrhoeae, termed pacA (peptidoglycan acetylase
A) [117]. PacA requires a related protein called PacB to acetylate the
C6-residue of MurNAc, leading to lysozyme resistance.
The enzyme responsible for deacetylation GlcNAc at the C2 residue
was ﬁrst identiﬁed in S. pneumoniae andwas termed PgdA (peptidogly-
can deacetylase A) [118]. Deacetylation is also discussed to contribute to
lysozyme resistance and PgdA was identiﬁed as a virulence factor
promoting intracellular survival within macrophages [118–120]. Fur-
thermore functional homologs were identiﬁed in E. faecalis [115],
Helicobacter pylori [121], and Listeria monocytogenes [120], based on
the contributions of these genes to lysozyme resistance.
Besides, linkage of secondary polymers such as teichoic acids, capsu-
lar polysaccharides or arabinogalactans to peptidoglycan strands is also
likely to be crucial for proper cell-wall architecture and integrity in
Gram-positive bacteria. The structure of the linkage between these
cell-wall polymers is known only for a limited number of bacterial
species, with a complete lack of knowledge of the enzymes responsible
for attachment of secondary cell-wall polymers to the glycan strands in
peptidoglycan.
4. Conclusion
The evolutionary success of AMPs is certainly associated with the
intrinsic cationic amphiphilicity which enables multiple and pleiotropic
effects on microbial membranes and membrane-embedded protein
machineries involved in biosynthetic, transport and energy generation
processes. The potency of AMPs can be greatly enhanced when such
mechanisms are combined with targeted activities such as lipid II-
mediated inhibition of cell wall biosynthesis. In a co-evolutionary
process, it appears obvious that a primary strategy of microbes for
counteracting AMP activities relies on interfering with the primary
adsorption of AMPs on the cell surface by masking anionic struc-
tures [122]. However, since a negative surface charge is vital, the level
of modiﬁcation of anionic structures is limited. Most chargemodulation
systems are therefore tightly regulated and are only active in the
presence of AMPs. Modiﬁcations in the peptidoglycan core structure,
however, tend to be constitutive and are often essential for the respec-
tivemicrobes as a result of enzyme evolution towards themodiﬁed sub-
strates. Such cell envelope modiﬁcations can equally contribute to
reduction of cell surface charge, e.g. the amidation of Glu in the stem
peptide.
The respective modiﬁcation enzymes may therefore constitute
interesting targets for new anti-infectives, directed to re-sensitizingmi-
crobes to innate defenses and to develop novel bactericidal drugs as
well as their optimization.
Overall, a successful antibacterial drug discovery in the future
requires a deeper understanding of the molecular organization of the
biosynthesis machinery itself and its the species-speciﬁc modiﬁcations
of the target structures and its interconnectionswith other vital cellular
processes.
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